

Matthias Orth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8560990/publications.pdf>

Version: 2024-02-01

77
papers

2,003
citations

471477

17
h-index

243610

44
g-index

79
all docs

79
docs citations

79
times ranked

2297
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of Human Apolipoprotein E3 or E4 in the Brains of <i>ApoE</i> Mice: Isoform-Specific Effects on Neurodegeneration. <i>Journal of Neuroscience</i> , 1999, 19, 4867-4880.	3.6	334
2	Isoform-specific effects of human apolipoprotein E on brain function revealed in <i>ApoE</i> knockout mice: Increased susceptibility of females. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10914-10919.	7.1	331
3	Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth. <i>Journal of Biological Chemistry</i> , 1995, 270, 27063-27071.	3.4	285
4	Cholesterol: Its Regulation and Role in Central Nervous System Disorders. <i>Cholesterol</i> , 2012, 2012, 1-19.	1.6	228
5	Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. <i>FEBS Journal</i> , 1989, 181, 657-662.	0.2	153
6	A New Concept for Acne Therapy: A Pilot Study With Zileuton, an Oral 5-Lipoxygenase Inhibitor. <i>Archives of Dermatology</i> , 2003, 139, 668-70.	1.4	96
7	Postprandial chylomicrons and VLDLs in severe hypertriglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n^{-3} fatty acids. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 914-920.	4.7	72
8	The use of error and uncertainty methods in the medical laboratory. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 209-219.	2.3	66
9	Effects of a Frequent Apolipoprotein E Isoform, ApoE4 _{Freiburg} (Leu28 ⁺ Pro), on Lipoproteins and the Prevalence of Coronary Artery Disease in Whites. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1306-1315.	2.4	38
10	Opinion: redefining the role of the physician in laboratory medicine in the context of emerging technologies, personalised medicine and patient autonomy ($\hat{4}$ P medicine TM). <i>Journal of Clinical Pathology</i> , 2019, 72, 191-197.	2.0	36
11	Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. <i>Clinical Biochemistry</i> , 2014, 47, 1069-1077.	1.9	32
12	Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype. <i>Lipids and Lipid Metabolism</i> , 1996, 1303, 22-30.	2.6	31
13	Comparability and Imprecision of 8 Frequently Used Commercially Available Immunoassays for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 433-441.	2.0	29
14	Autoverification of test results in the core clinical laboratory. <i>Clinical Biochemistry</i> , 2019, 73, 11-25.	1.9	24
15	Multicenter Analytical Evaluation of the Automated Electrochemiluminescence Immunoassay for Cyclosporine. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 640-650.	2.0	23
16	Human serum gangliosides in hypercholesterolemia, before and after extracorporeal elimination of LDL. <i>Atherosclerosis</i> , 1992, 94, 109-117.	0.8	20
17	Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability. <i>Thrombosis Research</i> , 1995, 79, 297-305.	1.7	18
18	Implementation of the new EU IVD regulation ⁴ urgent initiatives are needed to avert impending crisis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, .	2.3	18

#	ARTICLE	IF	CITATIONS
19	The Diagnostic Value of Serum Homocysteine Concentration as a Risk Factor for Coronary Artery Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 453-7.	2.3	16
20	Commutability Assessment of Candidate Reference Materials for Pancreatic Î±-Amylase. <i>Clinical Chemistry</i> , 2018, 64, 1193-1202.	3.2	15
21	Altered concentrations, patterns and distribution in lipoproteins of serum gangliosides in liver diseases of different etiologies. <i>Journal of Hepatology</i> , 1990, 11, 290-296.	3.7	12
22	Fluorometric determination of total retinyl esters in triglyceride-rich lipoproteins. <i>Clinical Chemistry</i> , 1998, 44, 1459-1465.	3.2	12
23	Quantitative laboratory results: normal or lognormal distribution?. <i>Journal of Laboratory Medicine</i> , 2020, 44, 143-150.	1.1	12
24	Shed L-Selectin (sCD62L) Load in Trauma Patients. <i>Journal of Surgical Research</i> , 2001, 99, 321-327.	1.6	10
25	Praktische Umsetzung des Gendiagnostikgesetzes (GenDG) in der Laboratoriumsmedizin, dem humangenetischen Laboratorium und der humangenetischen Beratung/Practical Implications of the German Genetic Diagnostics Act (GenDG) for Laboratory Medicine, the Human Genetics Laboratory and for Genetic Counseling. <i>Laboratoriums Medizin</i> , 2011, 35, 243-253.	0.6	10
26	Der zlog-Wert als Basis für die Standardisierung von Laborwerten. <i>Laboratoriums Medizin</i> , 2017, 41, 23-32.	0.6	10
27	Are regulation-driven performance criteria still acceptable? – The German point of view. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 893-8.	2.3	7
28	cAMP-induced expression of ABCA1 is associated with MAP-kinase-pathway activation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 89-94.	2.1	6
29	Standard-Arbeitsanleitung zur peripher venösen Blutentnahme für die labormedizinische Diagnostik. <i>Laboratoriums Medizin</i> , 2017, 41, 333-340.	0.6	6
30	Age and sex dependent reference intervals for random plasma/serum glucose concentrations related to different sampling devices and determined by an indirect procedure with data mining. <i>Journal of Laboratory Medicine</i> , 2021, 45, 95-101.	1.1	6
31	Chylomicron Remnant Concentrations in Patients with Coronary Artery Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 652-62.	2.3	5
32	The zlog value as a basis for the standardization of laboratory results. <i>Laboratoriums Medizin</i> , 2017, 41, .	0.6	5
33	Chancen und Risiken von e-Health in der Labormedizin. <i>Laboratoriums Medizin</i> , 2016, 40, 227-237.	0.6	4
34	Responsiveness of ATIII and coagulation factors V and VII to a standardized oral fat load. <i>Thrombosis Research</i> , 1995, 80, 265-270.	1.7	3
35	Rapid Factor XII (46Câ†T) Genotyping by Fluorescence Resonance Energy Transfer in Patients with Coronary Artery Disease or Thrombophilia. <i>Clinical Chemistry</i> , 2001, 47, 1117-1119.	3.2	3
36	CSF interleukin 6 – a useful biomarker of meningitis in adults?/ Liquor Interleukin 6 – ein sinnvoller Biomarker für die Meningitis beim Erwachsenen. <i>Laboratoriums Medizin</i> , 2011, 35, 107-113.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Effects of different tube types on patient classification using current diabetes decision limits. <i>Practical Laboratory Medicine</i> , 2019, 17, e00134.	1.3	3
38	Hemostatic Factors in Hypertriglyceridemic Men. <i>Thrombosis Research</i> , 1999, 94, 341-351.	1.7	2
39	An improved method for the rapid assessment of persisting chylomicron remnant concentrations. <i>Clinical Biochemistry</i> , 2001, 34, 387-394.	1.9	2
40	Direct-to-Consumer Testing. <i>Point of Care</i> , 2017, 16, 124-127.	0.4	2
41	Schnelltests: Mit Bedacht einsetzen. , 0, , .		2
42	Direct to Consumer Laboratory Testing (DTCT) - Opportunities and Concerns. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2021, 32, 209-215.	0.7	2
43	Gemfibrozil exerts favorable trends on parameters of glucose tolerance in hyperlipidemic patients suffering from diabetes mellitus. <i>Atherosclerosis</i> , 1994, 109, 249.	0.8	1
44	Endocytosis and intracellular trafficking of fatty acid esters of phenylaminopropanediol, the putative etiologic agents of the toxic oil syndrome (TOS). <i>Toxicology Letters</i> , 2006, 163, 206-212.	0.8	1
45	Quality in Laboratory Hemostasis and Thrombosis. <i>Laboratoriums Medizin</i> , 2011, 35, 219-220.	0.6	1
46	Pro und Contra der Thrombophiliediagnostik/Pros and cons of thrombophilia testing. <i>Laboratoriums Medizin</i> , 2013, 37, 67-78.	0.6	1
47	Empfehlungen zur Häufigkeit der Anforderung von Laboruntersuchungen. <i>Laboratoriums Medizin</i> , 2014, 38, 231-238.	0.6	1
48	Requirements for electronic laboratory reports according to the German guideline Rili-BAEK and ISO 15189. <i>Journal of Laboratory Medicine</i> , 2021, 45, 197-203.	1.1	1
49	Diagnostic work up of anemic patients: role of iron deficiency. <i>Journal of Laboratory Medicine</i> , 2020, 44, 175-182.	1.1	1
50	Biosynthesis and secretion of gangliosides by the isolated perfused rat liver. <i>Journal of Hepatology</i> , 1989, 9, S225.	3.7	0
51	Pravastatin treatment decreases postprandial levels of chylomicron remnants in type IIb patients. <i>Atherosclerosis</i> , 1994, 109, 126.	0.8	0
52	Late chylomicron remnants after a standardized oral fat load do not discriminate between patients with coronary heart disease and healthy controls. <i>Atherosclerosis</i> , 1995, 115, S8.	0.8	0
53	Postprandial heparin-induced free fatty acids discriminate between patients with and without coronary artery disease. <i>Atherosclerosis</i> , 1995, 115, S8.	0.8	0
54	Apo E and apo CIII from different lipoproteins in the HDL size range and behave differently in secondary dyslipoproteinemias. <i>Atherosclerosis</i> , 1995, 115, S69.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Lack of interference of apo(a) polymorphism in nephelometric LP(a) determination. <i>Atherosclerosis</i> , 1995, 115, S87.	0.8	0
56	Diagnostic Pitfalls during Therapy for Extreme Hypertriglyceridaemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 1997, 35, 101-3.	2.3	0
57	Thrombophiliediagnostik bei EmpfÄngern von Organtransplantaten / Thrombophilia diagnostics in recipients of organ transplants. <i>Laboratoriums Medizin</i> , 2004, 28, 28-33.	0.6	0
58	Cytokines in the Genesis and Treatment of Cancer. <i>Laboratoriums Medizin</i> , 2008, 32, 41.	0.6	0
59	Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der PrÄvention und Therapie von Thrombosen. <i>Laboratoriums Medizin</i> , 2009, 33, 121-127.	0.6	0
60	Thrombozytenhemmende Therapie in der Kardiologie: aktuelle Entwicklungen bei Therapie und Monitoring / Antiplatelet drugs in cardiology: current trends in therapy and monitoring. <i>Laboratoriums Medizin</i> , 2010, 34, 261-269.	0.6	0
61	Antibiotika am Krankenbett. <i>Laboratoriums Medizin</i> , 2011, 35, 173-174.	0.6	0
62	Einsatz der D-Dimerbestimmung â€“ ein Update/Update of D-dimer testing. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.6	0
63	Kennzahlen und Benchmarking im Krankenhauslabor/Key figures and benchmarking in the hospital laboratory. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.6	0
64		0.6	0
65	Umfrage zur Laborberatung in Deutschland. <i>Laboratoriums Medizin</i> , 2014, 38, .	0.6	0
66	Recommendations for the frequency of ordering laboratory testing. <i>Laboratoriums Medizin</i> , 2015, 38, .	0.6	0
67	Corrigendum zu: Chancen und Risiken von e-Health in der Labormedizin. <i>Laboratoriums Medizin</i> , 2016, 40, .	0.6	0
68	Festlegung der zulÄssigen Messunsicherheit quantitativer MessgrÄÄen in der Laboratoriumsmedizin. <i>Laboratoriums Medizin</i> , 2017, 41, 53-58.	0.6	0
69	Letter to the editor by Winter et al.: Reply. <i>Laboratoriums Medizin</i> , 2018, 42, 63-65.	0.6	0
70	Long-term medical data storage: challenges with test results obtained by direct-to-consumer testing. <i>Laboratoriums Medizin</i> , 2018, 42, 235-242.	0.6	0
71	Quintessence Unjustified. <i>Deutsches A&#x0308;rztblatt International</i> , 2010, 107, 215; author reply 215-6.	0.9	0
72	Unsatisfactory Quality. <i>Deutsches A&#x0308;rztblatt International</i> , 2011, 108, 129; author reply 129-30.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Prevention of CA-MRSA. Deutsches Ärztblatt International, 2012, 109, 282; author reply 282.	0.9	0
74		0.6	0
75	Up-to date platelet testing. Journal of Laboratory Medicine, 2020, 44, 227-230.	1.1	0
76	Avoiding insufficient therapies and overdosing with co-reporting eGFRs (estimated glomerular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 63. benefits. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2021, 32, 41-51.	0.7	0
77	Biomarker Troponin (2): Sicht des Labormediziners. , 0, , .		0